• ICG001: A Selective Wnt/β-Catenin Pathway Inhibitor

  2026-09-23

  ICG001 is a Wnt/β-catenin pathway inhibitor used to probe transcription driven by the β-catenin–CBP interaction. Its reported activity and research applications make it useful for pathway studies, but findings must be interpreted by model, assay conditions, and the distinction between preclinical evidence and clinical efficacy.

• CHIR-99021 (CT99021) in Stem Cell Signaling

  2026-09-23

  CHIR-99021, also called CT99021, is a selective GSK-3α/β inhibitor used to modulate Wnt/β-catenin signaling and stem-cell fate. Evidence supports concentration-sensitive use in pluripotency, lineage differentiation, and vascularized pancreatic progenitor workflows, but reported conditions are system-specific.

• Redox State Strategy for Hypoxic Tumors

  2026-09-22

  Hypoxia and immunometabolic competition can reshape tumor redox biology, but translational claims require direct measurement of glutathione pools. This thought-leadership guide connects tumor microenvironment mechanisms with experimental strategy, showing how the GSH and GSSG Assay Kit supports quantitative reduced glutathione detection, oxidized glutathione measurement, and reproducible redox state analysis.

• Reactive Oxygen Species Assay Kit in FLASH-RT

  2026-09-22

  Explore how the Reactive Oxygen Species Assay Kit and DCFH-DA fluorescent probe can connect treatment-induced redox changes with apoptosis, DNA damage, and immune effects in FLASH-radiotherapy research. This guide translates recent EGCG nanoparticle findings into practical assay design, controls, interpretation, and limitations.

• RRP Restores Lipid Metabolism After Hepatic IRI

  2026-09-21

  The reference study shows that Radix Rehmanniae Praeparata (RRP) extracts mitigate hepatic ischemia-reperfusion injury by correcting cholesterol synthesis and efflux, rather than relying only on general hepatoprotection. Its central mechanistic contribution is the identification of an AMPK–mTOR pathway that suppresses SCAP/SREBP2 activation through ERLIN1 and INSIG1 while promoting LXRα-dependent cholesterol efflux.

• Methylprednisolone Sodium Succinate Workflows

  2026-09-21

  Build reproducible inflammation, immune-cell, and tumor-response assays with a concentration-aware workflow for Methylprednisolone Sodium Succinate. The guide combines practical dosing, orthogonal readouts, and troubleshooting with a time-window strategy adapted from receptor pharmacology research.

• Cy5 TSA Fluorescence System Kit for DIC Research

  2026-09-20

  Use the Cy5 TSA Fluorescence System Kit to resolve weak endothelial, inflammasome, and cardiomyocyte signals in doxorubicin cardiotoxicity models. Its HRP-directed deposition workflow combines high sensitivity with spatial precision while conserving scarce antibodies and probes.

• 8-DY547-cGMP for CA2 cGMP Assays

  2026-09-19

  8-DY547-cGMP offers an exploratory fluorescence-based route for studying cyclic GMP binding, transport, or enzymatic turnover alongside Alzheimer’s disease models. This workflow pairs biochemical validation with the CA2 perineuronal-net biology reported in the reference study, while clearly separating established findings from assay-development hypotheses.

• BCECF-AM for V-ATPase-Linked pH Phenotyping

  2026-09-18

  BCECF-AM enables ratiometric intracellular pH measurement that can separate cytoplasmic physiology from vacuolar-acidification phenotypes. This article develops a control-driven assay framework for interpreting SINAT–VAB1 autophagy findings in Arabidopsis without overclaiming what a bulk fluorescence ratio can prove.

• Cisapride (R 51619) for Cardiac Screening

  2026-09-18

  Cisapride (R 51619) connects 5-HT4 receptor biology with hERG-focused cardiac safety testing, making it useful for mechanistic assays and phenotypic cardiotoxicity screens. This practical workflow shows how to combine iPSC-derived cardiomyocytes, high-content imaging, and orthogonal electrophysiology while controlling solvent, exposure, and assay-interpretation risks.

• AR and ARv7 in TNBC: EPI-001 Study Insights

  2026-09-17

  This 2025 study integrates patient pathology, TCGA-BRCA analysis, and MDA-MB-231 experiments to define AR and ARv7 as adverse features in triple-negative breast cancer. Its findings connect AR/ARv7 blockade with altered metastasis and epithelial-to-mesenchymal transition markers, supporting further evaluation of N-terminal AR targeting while remaining preclinical.

• AZD1390: Reading G4-Driven DNA Damage

  2026-09-17

  AZD1390 is an ATM kinase inhibitor that can expose how G-quadruplex replication stress becomes checkpoint failure after radiation. This article presents a time-resolved assay strategy that separates G4 persistence, ATM signaling, and radiosensitization in cancer research.

• Trichostatin A (TSA) in Organoid Assays

  2026-09-16

  Trichostatin A (TSA) is more than a conventional HDAC inhibitor: it can serve as a controlled perturbation for linking chromatin acetylation with proliferation and differentiation. This article translates a tunable human intestinal organoid study into practical assay-design principles while distinguishing established evidence from testable hypotheses.

• Isoprenaline Hydrochloride: From β-Agonism to Assay Design

  2026-09-16

  Isoprenaline Hydrochloride, also known as isoproterenol, is more than a cardiac stimulant: it is a controllable perturbation tool for linking β-adrenergic signaling to cardiovascular, endothelial, and heart–brain phenotypes. This guide translates recent PTSD-model findings into practical assay-design decisions, controls, and interpretation strategies.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer

  2026-09-15

  A 2026 FASEB Journal study developed chemically modified CDKN1A/p21 mRNA in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21 expression, suppressed tumor-associated cell-cycle programs, and reduced tumor growth in an orthotopic mouse model while limiting systemic distribution.

7915 records 1/528 page Next 12345 下5页 Last page